Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022 -57.8% Revenue growth, 20223 Where the money goes Where each dollar of revenue went, fiscal 2022 Cost of revenue Research and development
Cost of revenue 81¢ $28.4M Research and development 18¢ $6.2M Interest 1¢ $316.0K Income tax 0¢ $125.0K Out of $25.9M in revenue.3
Financial statements
Income statement Balance sheet Cash flow
Annual Quarterly
Revenue4 5 6 7 8 3 $25.9M in 2022+702% since 2016 0 $20.0M $40.0M $60.0M $80.0M 2016: $3.2M $3.2M 2016 2017: $5.1M $5.1M 2017 +57% 2018: $3.3M $3.3M 2018 −36% 2019: $5.5M $5.5M 2019 +70% 2020: $27.5M $27.5M 2020 +397% 2021: $61.2M $61.2M 2021 +123% 2022: $25.9M $25.9M 2022 −58% Operating income4 5 6 7 8 3 -$32.0M in 2022+77% since 2016 -$40.0M -$30.0M -$20.0M -$10.0M 0 2016: -$18.0M -$18.0M 2016 2017: -$21.2M -$21.2M 2017 +17% 2018: -$24.3M -$24.3M 2018 +15% 2019: -$23.1M -$23.1M 2019 −5% 2020: -$15.5M -$15.5M 2020 −33% 2021: -$2.4M -$2.4M 2021 −84% 2022: -$32.0M -$32.0M 2022 +1228% Net income4 5 6 7 8 3 -$32.1M in 2022+74% since 2016 -$40.0M -$30.0M -$20.0M -$10.0M 0 2016: -$18.4M -$18.4M 2016 2017: -$21.6M -$21.6M 2017 +17% 2018: -$24.6M -$24.6M 2018 +14% 2019: -$25.1M -$25.1M 2019 +2% 2020: -$17.8M -$17.8M 2020 −29% 2021: -$2.8M -$2.8M 2021 −84% 2022: -$32.1M -$32.1M 2022 +1036% Revenue9 10 $589.0K in Q2 FY2023−12% since Q1 FY2023 0 $200.0K $400.0K $600.0K $800.0K Q1 FY2023: $673.0K $673.0K Q1 FY2023 Q2 FY2023: $589.0K $589.0K Q2 FY2023 −12% Operating income9 10 -$6.1M in Q2 FY2023−14% since Q1 FY2023 -$8.0M -$6.0M -$4.0M -$2.0M 0 Q1 FY2023: -$7.1M -$7.1M Q1 FY2023 Q2 FY2023: -$6.1M -$6.1M Q2 FY2023 −14% Net income9 10 -$3.6M in Q2 FY2023−49% since Q1 FY2023 -$8.0M -$6.0M -$4.0M -$2.0M 0 Q1 FY2023: -$7.1M -$7.1M Q1 FY2023 Q2 FY2023: -$7.1M -$7.1M Q2 FY2023 +0% Q2 FY2023: -$3.6M -$3.6M Q2 FY2023 −49% Fiscal year 2016 2017 2018 2019 2020 2021 2022 Revenue $3.2M4 $5.1M5 $3.3M6 $5.5M7 $27.5M8 $61.2M3 $25.9M3 Cost of revenue $6.9M4 $9.3M5 $10.1M6 $11.0M7 $21.3M8 $37.8M3 $28.4M3 Gross profit Research and development $2.7M4 $3.4M5 $4.5M6 $4.7M7 $5.2M8 $5.0M3 $6.2M3 Operating income -$18.0M4 -$21.2M5 -$24.3M6 -$23.1M7 -$15.5M8 -$2.4M3 -$32.0M3 Interest $525.9K4 $482.6K5 $311.0K6 $250.0K7 $236.0K8 $290.0K3 $316.0K3 Income tax $2.1K4 $7.6K5 $1.9K6 $125.0K3 -$125.0K3 Net income -$18.4M4 -$21.6M5 -$24.6M6 -$25.1M7 -$17.8M8 -$2.8M3 -$32.1M3 Earnings per share -$1.924 -$23.585 -$9.016 -$12.237 -$1.508 -$0.193 -$1.893 Earnings per share (diluted) -$1.924 -$23.585 -$9.016 -$12.237 -$1.508 -$0.193 -$1.893
Total assets4 5 6 7 8 3 $30.9M in 2022+307% since 2016 0 $20.0M $40.0M $60.0M $80.0M 2016: $7.6M $7.6M 2016 2017: $7.4M $7.4M 2017 −3% 2018: $8.8M $8.8M 2018 +19% 2019: $17.7M $17.7M 2019 +103% 2020: $47.5M $47.5M 2020 +168% 2021: $60.4M $60.4M 2021 +27% 2022: $30.9M $30.9M 2022 −49% Total liabilities4 5 6 7 8 3 $22.0M in 2022+218% since 2016 0 $10.0M $20.0M $30.0M 2016: $6.9M $6.9M 2016 2017: $6.1M $6.1M 2017 −12% 2018: $5.7M $5.7M 2018 −6% 2019: $6.5M $6.5M 2019 +14% 2020: $23.8M $23.8M 2020 +264% 2021: $22.9M $22.9M 2021 −3% 2022: $22.0M $22.0M 2022 −4% Shareholders’ equity5 6 7 8 3 $8.9M in 2022+1245% since 2016 0 $10.0M $20.0M $30.0M $40.0M 2016: $658.7K $658.7K 2016 2017: $1.3M $1.3M 2017 +97% 2018: $3.0M $3.0M 2018 +135% 2019: $11.2M $11.2M 2019 +268% 2020: $23.7M $23.7M 2020 +112% 2021: $37.5M $37.5M 2021 +58% 2022: $8.9M $8.9M 2022 −76% Total assets9 10 $22.1M in Q2 FY2023−28% since Q1 FY2022 0 $10.0M $20.0M $30.0M $40.0M Q1 FY2022: $30.9M $30.9M Q1 FY2022 Q2 FY2022: $30.9M $30.9M Q2 FY2022 +0% Q1 FY2023: $23.0M $23.0M Q1 FY2023 −26% Q2 FY2023: $22.1M $22.1M Q2 FY2023 −4% Total liabilities9 10 $21.8M in Q2 FY2023−1% since Q1 FY2022 0 $10.0M $20.0M $30.0M Q1 FY2022: $22.0M $22.0M Q1 FY2022 Q2 FY2022: $22.0M $22.0M Q2 FY2022 +0% Q1 FY2023: $20.6M $20.6M Q1 FY2023 −7% Q2 FY2023: $21.8M $21.8M Q2 FY2023 +6% Shareholders’ equity9 10 $290.0K in Q2 FY2023−97% since Q1 FY2022 0 $2.5M $5.0M $7.5M $10.0M Q1 FY2022: $8.9M $8.9M Q1 FY2022 Q2 FY2022: $8.9M $8.9M Q2 FY2022 +0% Q1 FY2023: $2.4M $2.4M Q1 FY2023 −73% Q2 FY2023: $2.4M $2.4M Q2 FY2023 +0% Q2 FY2023: $290.0K $290.0K Q2 FY2023 −88% Fiscal year 2016 2017 2018 2019 2020 2021 2022 Cash Current assets $5.8M4 $4.3M5 $6.0M6 $13.9M7 $32.6M8 $45.7M3 $16.3M3 Total assets $7.6M4 $7.4M5 $8.8M6 $17.7M7 $47.5M8 $60.4M3 $30.9M3 Current liabilities $4.4M4 $4.7M5 $4.6M6 $5.6M7 $12.5M8 $11.8M3 $5.5M3 Total liabilities $6.9M4 $6.1M5 $5.7M6 $6.5M7 $23.8M8 $22.9M3 $22.0M3 Shareholders’ equity $658.7K5 $1.3M6 $3.0M7 $11.2M8 $23.7M3 $37.5M3 $8.9M3 Shares outstanding 17.5M shares4 1.2M shares5 4.6M shares6 5.5M shares7 13.4M shares8 16.8M shares3 17.1M shares3
Cash from operations5 6 7 8 3 -$13.3M in 2022−32% since 2017 -$30.0M -$20.0M -$10.0M 0 $10.0M 2017: -$19.7M -$19.7M 2017 2018: -$22.4M -$22.4M 2018 +14% 2019: -$23.0M -$23.0M 2019 +3% 2020: -$19.8M -$19.8M 2020 −14% 2021: $3.7M $3.7M 2021 2022: -$13.3M -$13.3M 2022 Capital spending4 5 6 7 8 3 $807.0K in 2022+67% since 2016 0 $500.0K $1.0M $1.5M $2.0M 2016: $482.1K $482.1K 2016 2017: $1.4M $1.4M 2017 +190% 2018: $145.3K $145.3K 2018 −90% 2019: $735.3K $735.3K 2019 +406% 2020: $867.0K $867.0K 2020 +18% 2021: $1.6M $1.6M 2021 +81% 2022: $807.0K $807.0K 2022 −49% Free cash flow5 6 7 8 3 -$14.1M in 2022−33% since 2017 -$30.0M -$20.0M -$10.0M 0 $10.0M 2017: -$21.1M -$21.1M 2017 2018: -$22.5M -$22.5M 2018 +7% 2019: -$23.8M -$23.8M 2019 +6% 2020: -$20.7M -$20.7M 2020 −13% 2021: $2.1M $2.1M 2021 2022: -$14.1M -$14.1M 2022 Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Fiscal year 2016 2017 2018 2019 2020 2021 2022 Cash from operations -$19.7M5 -$22.4M6 -$23.0M7 -$19.8M8 $3.7M3 -$13.3M3 Capital spending $482.1K4 $1.4M5 $145.3K6 $735.3K7 $867.0K8 $1.6M3 $807.0K3 Free cash flow -$21.1M -$22.5M -$23.8M -$20.7M $2.1M -$14.1M
Compare BIOCEPT INC with another company
Recent filings
Oct 20, 2023 8-K Oct 16, 2023 8-K Aug 22, 2023 8-K Aug 14, 2023 10-Q Jun 21, 2023 8-K Jun 20, 2023 3 FORM 3 SUBMISSIONMay 23, 2023 S-1/A May 19, 2023 S-1/A May 16, 2023 8-K May 16, 2023 S-1/A May 15, 2023 8-K May 15, 2023 S-1/A May 10, 2023 10-Q Apr 20, 2023 DEF 14A Apr 20, 2023 S-1 Every filing from the last three years, summarized . The full record is on SEC EDGAR.1
